Double-Action Antibiotic Advances In GSK's Pipeline
Dosing Starts In Phase III Gepotidacin Studies
GlaxoSmithKline has initiated Phase III studies, EAGLE-1 and EAGLE-2, of potentially a new chemical class of oral antibiotic in patients with infections of public health concern, gonorrhea and urinary tract infections.
You may also be interested in...
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.